These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 14513286

  • 1. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masauzi N.
    Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
    [Abstract] [Full Text] [Related]

  • 2. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H, Cai Q, Lin T, Lin X, Liu Y, Gao Y, Peng R.
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [Abstract] [Full Text] [Related]

  • 3. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK.
    J Clin Oncol; 2009 Feb 01; 27(4):605-11. PubMed ID: 19075267
    [Abstract] [Full Text] [Related]

  • 4. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B.
    Haematologica; 2003 Nov 01; 88(11):1296-303. PubMed ID: 14607759
    [Abstract] [Full Text] [Related]

  • 5. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST.
    Ann Hematol; 2011 Oct 01; 90(10):1219-23. PubMed ID: 21520001
    [Abstract] [Full Text] [Related]

  • 6. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.
    Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY.
    Ann Hematol; 2010 Mar 01; 89(3):255-62. PubMed ID: 19697028
    [Abstract] [Full Text] [Related]

  • 7. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM.
    Ann Hematol; 2004 Dec 01; 83(12):769-74. PubMed ID: 15338194
    [Abstract] [Full Text] [Related]

  • 8. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
    Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ.
    Ann Hematol; 2004 May 01; 83(5):270-5. PubMed ID: 15060745
    [Abstract] [Full Text] [Related]

  • 9. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Endo T, Sakai T, Fujimoto K, Yamamoto S, Takashima H, Haseyama Y, Nishio M, Koizumi K, Koike T, Sawada K.
    Bone Marrow Transplant; 2001 Feb 01; 27(4):433-6. PubMed ID: 11313673
    [Abstract] [Full Text] [Related]

  • 10. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zou S.
    Eur J Haematol; 2010 Sep 01; 85(3):243-50. PubMed ID: 20491883
    [Abstract] [Full Text] [Related]

  • 11. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
    Mimura N, Tsujimura H, Ise M, Sakai C, Kojima H, Fukai K, Yokosuka O, Takagi T, Kumagai K.
    Rinsho Ketsueki; 2009 Dec 01; 50(12):1715-9. PubMed ID: 20068280
    [Abstract] [Full Text] [Related]

  • 12. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.
    He YF, Li YH, Wang FH, Jiang WQ, Xu RH, Sun XF, Xia ZJ, Huang HQ, Lin TY, Zhang L, Bao SP, He YJ, Guan ZZ.
    Ann Hematol; 2008 Jun 01; 87(6):481-5. PubMed ID: 18299831
    [Abstract] [Full Text] [Related]

  • 13. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
    Ahmed A, Keeffe EB.
    Am J Gastroenterol; 1999 Jan 01; 94(1):249-51. PubMed ID: 9934765
    [Abstract] [Full Text] [Related]

  • 14. Reactivation of hepatitis B virus with rituximab.
    Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N.
    Expert Opin Drug Saf; 2005 May 01; 4(3):599-608. PubMed ID: 15934864
    [Abstract] [Full Text] [Related]

  • 15. [Lamivudine for the prevention of chronic hepatitis B exacerbations during chemotherapy for non-Hodgkin's lymphoma].
    van der Eijk AA, Doorduijn JK, Janssen HL, Schalm SW, Niesters HG, de Man RA.
    Ned Tijdschr Geneeskd; 2002 Jun 15; 146(24):1140-4. PubMed ID: 12092307
    [Abstract] [Full Text] [Related]

  • 16. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y, Yu SJ, Cho EJ, Lee JH, Kim TM, Heo DS, Kim YJ, Yoon JH.
    J Med Virol; 2016 Jun 15; 88(6):1010-7. PubMed ID: 26531242
    [Abstract] [Full Text] [Related]

  • 17. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM, Huang YH, Lee PC, Lin HC, Lee SD.
    J Clin Gastroenterol; 2009 Jun 15; 43(5):496-8. PubMed ID: 19247200
    [Abstract] [Full Text] [Related]

  • 18. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.
    Ann Rheum Dis; 2011 Oct 15; 70(10):1719-25. PubMed ID: 21719446
    [Abstract] [Full Text] [Related]

  • 19. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
    Schnepf N, Sellier P, Bendenoun M, Zini JM, Sanson-le Pors MJ, Mazeron MC.
    J Clin Virol; 2007 May 15; 39(1):48-50. PubMed ID: 17368969
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.